Tonix Pharmaceuticals CEO Dr Seth Lederman tells Proactive's Stephen Gunnion the first patient has been enrolled in the Phase 2 CATALYST study involving TNX-1300, a novel therapy aimed at reversing the effects of cocaine intoxication. Lederman highlighted that this study, supported by the National Institute on Drug Abuse (NIDA), is a significant step forward in addressing the urgent issue of cocaine-related emergencies, which currently lack effective direct treatments. Lederman explained that TNX-1300 works by breaking down cocaine in the bloodstream, rendering it inactive and mitigating its dangerous effects. He also discussed the previous Phase 2A study where TNX-1300 showed compelling results in reversing cocaine's impact in a controlled laboratory setting. The Phase 2B study, according to Lederman, could yield results as soon as 2025, with potential pivotal implications for the treatment's future. Lederman also touched on the broader issue of cocaine intoxication in the US, noting that it often involves mixed drugs, such as cocaine combined with fentanyl, which complicates treatment and increases risks. The interview concluded with Lederman expressing optimism about the study’s progress and its potential to fill a critical gap in emergency care. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #CocaineAddiction #TNX1300 #ClinicalTrial #DrugAbuse #SethLederman #FDAApproval #PharmaNews #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews